SCHEMBL888243

SCHEMBL888243

O=C(CCCCCNC(=O)C(F)(F)F)ON1C(=O)CCC1=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
SMN1; SMN2 Q16637 3/20 0.49
ALDH1A1 P00352 2/20 0.49
POLB P06746 1/20 0.49
EPHX1 P07099 1/20 0.45
CA3 P07451 2/20 0.44
CA5A P35218 2/20 0.44
CA5B Q9Y2D0 2/20 0.44
CA14 Q9ULX7 2/20 0.44
CA12 O43570 1/20 0.44
CA2 P00918 1/20 0.44
CA4 P22748 1/20 0.44
CA6 P23280 1/20 0.44
CA7 P43166 1/20 0.44
CA9 Q16790 1/20 0.44
HPGD P15428 2/20 0.35
HTT P42858 1/20 0.35
NQO2 P16083 3/20 0.34
MTNR1A P48039 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2100045 1.00 MEN1 (0.51) MEN1KMT2ASMN1; SMN2ALDH1A1POLB
SCHEMBL7699524 0.94 SMN1; SMN2 (0.47) MEN1KMT2ASMN1; SMN2ALDH1A1POLB
SCHEMBL6129080 0.89 ALDH1A1 (0.42) MEN1KMT2ASMN1; SMN2ALDH1A1POLB
SCHEMBL5492139 0.83 SMN1; SMN2 (0.38) MEN1KMT2ASMN1; SMN2ALDH1A1HPGD
SCHEMBL17767812 0.83 SMN1; SMN2 (0.50) SMN1; SMN2ALDH1A1HPGDHTTHDAC8
SCHEMBL17767809 0.83 SMN1; SMN2 (0.50) SMN1; SMN2ALDH1A1HPGDHTTHDAC8
SCHEMBL26382038 0.83 SMN1; SMN2 (0.50) SMN1; SMN2ALDH1A1HPGDHTTHDAC8
SCHEMBL17168743 0.83 SMN1; SMN2 (0.50) SMN1; SMN2ALDH1A1HPGDHTTHDAC8
SCHEMBL20999873 0.83 SMN1; SMN2 (0.50) SMN1; SMN2ALDH1A1HPGDHTTHDAC8
SCHEMBL2615833 0.82 ADRA1A (0.47) KMT2ASMN1; SMN2HPGDHTTNAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120296087-A1 MORPHOLINO-BASED ANTISENSE AGENT INDIAN ASSOCIATION FOR THE CULTIVATION OF SCIENCE (IN) 2012-11-22 US claimed
US-20260125413-A1 UNIVERSAL SOLID SUPPORTS AND PHOSPHORAMIDITE BUILDING BLOCKS FOR OLIGONUCLEOTIDE SYNTHESIS AM CHEMICALS LLC (US) 2026-05-07 US disclosed
EP-4577539-A1 UNIVERSAL SOLID SUPPORTS AND PHOSPHORAMIDITE BUILDING BLOCKS FOR OLIGONUCLEOTIDE SYNTHESIS AM Chemicals Llc (US) 2025-07-02 EP disclosed
WO-2024044792-A1 UNIVERSAL SOLID SUPPORTS AND PHOSPHORAMIDITE BUILDING BLOCKS FOR OLIGONUCLEOTIDE SYNTHESIS AM CHEMICALS LLC (US) 2024-02-29 WO disclosed
US-20210139976-A1 NUCLEOTIDE ANALOGUES AND USE THEREOF FOR NUCLEIC ACID SEQUENCING AND ANALYSIS THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2021-05-13 US disclosed
US-10808246-B2 Oligonucleotide-ligand conjugates and process for their preparation ALNYLAM PHARMACEUTICALS, INC. (US) 2020-10-20 US disclosed
US-10167391-B2 Azo compound, use thereof and method for preparing same BIONEER CORPORATION (KR) 2019-01-01 US disclosed
US-9914745-B2 Morpholino-based antisense agent INDIAN ASSOCIATION FOR THE CULTIVATION OF SCIENCE (IN) 2018-03-13 US disclosed
US-20170016050-A1 NOVEL AZO COMPOUND, USE THEREOF AND METHOD FOR PREPARING SAME BIONEER CORPORATION (KR) 2017-01-19 US disclosed
US-20160376585-A1 OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION BANK OF AMERICA, N.A. 2016-12-29 US disclosed
US-6878552-B1 Homogeneous detection and/or determination method for a chemical or physico-chemical interaction CIS BIO INTERNATIONAL FRENCH JOINT STOCK COMPANY (FR) 2005-04-12 US disclosed
EP-0954606-B1 NON-NUCLEOTIDE LINKING REAGENTS BIOGENEX LAB (US) 2003-10-15 EP disclosed
EP-1235851-A2 REGULATORS OF THE HEDGEHOG PATHWAY, COMPOSITIONS AND USES RELATED THERETO Johns Hopkins University School of Medicine (US) 2002-09-04 EP disclosed
WO-2001027135-A9 REGULATORS OF THE HEDGEHOG PATHWAY, COMPOSITIONS AND USES RELATED THERETO UNIV JOHNS HOPKINS MED (US) 2002-08-15 WO disclosed
US-6340747-B1 COMPLEXED TO RARE EARTH METAL CRYPTATE LABEL; DETECTION AND ISOLATION OF NUCLEIC ACIDS CIS BIO INTERNATIONAL (FR) 2002-01-22 US disclosed
WO-2001027135-A2 REGULATORS OF THE HEDGEHOG PATHWAY, COMPOSITIONS AND USES RELATED THERETO JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) 2001-04-19 WO disclosed
US-6130323-A Non-nucleotide linking reagents BIOGENEX LABORATORIES (US) 2000-10-10 US disclosed
US-5190864-A Support-leash-enzyme conjugates, small amount of free enzyme releases large amount of bound enzyme NORTHEASTERN UNIVERSITY (US) 1993-03-02 US disclosed
US-4937188-A Enzyme activity amplification method for increasing assay sensitivity NORTHEASTERN UNIVERSITY (US) 1990-06-26 US disclosed
EP-0243797-A2 Method for amplifying enzyme activity, enzyme conjugates suitable therefor and their preparation NORTHEASTERN UNIVERSITY (US) 1987-11-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160376585-A1 OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION IGF2R, IRS1, INSR MEN1 2300/4885KMT2A 2534/4885SMN1; SMN2 1128/4885
US-10808246-B2 Oligonucleotide-ligand conjugates and process for their preparation RTCB, IGF2BP2, SNRPE MEN1 2721/4885KMT2A 2695/4885SMN1; SMN2 1621/4885
US-20120296087-A1 MORPHOLINO-BASED ANTISENSE AGENT MYOF, OSBP2, SLCO2B1 MEN1 3525/4885KMT2A 3562/4885SMN1; SMN2 874/4885
US-20260125413-A1 UNIVERSAL SOLID SUPPORTS AND PHOSPHORAMIDITE BUILDING BLOCKS FOR OLIGONUCLEOTIDE SYNTHESIS SSU72, NSUN2, POLR2H MEN1 3172/4885KMT2A 1229/4885SMN1; SMN2 755/4885
US-20210139976-A1 NUCLEOTIDE ANALOGUES AND USE THEREOF FOR NUCLEIC ACID SEQUENCING AND ANALYSIS NUDT1, NT5C3B, RNGTT MEN1 2372/4885KMT2A 1507/4885SMN1; SMN2 1461/4885
US-10167391-B2 Azo compound, use thereof and method for preparing same CRY1, CYP51A1, CYP3A4 MEN1 706/4885KMT2A 583/4885SMN1; SMN2 4826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.